The Inflammasome: a Novel Biomarker in ALI/ARDS

Investigator: Michael A. Matthay, MD
Sponsor: Brigham and Women's Hospital

Location(s): United States


The inflammasome has recently been described as an important protein complex in which A non-NFkB- mediated Signaling pathway leads to Up-Regulation of key pro-inflammatory cytokines, including interleukin (IL)- 1b and IL-18. Members of our group recently reported that The inflammasome plays Acritical Role in pro- Inflammatory response in Murine Sepsis, and this response is dependent upon mitochondrial integrity and an intact autophagy response to injury. We now present Data supporting an important Role for The inflammasome in predicting severity and Mortality during Human infection-related Ali/Ards. Moreover, our preliminary animal studies demonstrate that statins exacerbate lung injury and Inflammation via activation of The inflammasome. We therefore hypothesize that activation of Theinflammasome plays A critical Role in The Development of infection-related Ali/Ards and that statin administration may increase inflammasome-related downstream cytokines during lung injury. in particular, our collaboration with The ARDSnet SAILS trial Investigators (A randomized trial of statins vs. placebo in infection-relatedAli/Ards) in this Ancillary Studies in Clinical Trials RFA (HL-12-012) provides A unique opportunity to obtain additional collection of key Human samples to Address these important processes. We therefore propose: Specific Aim 1: To determine gene expression and protein levels of The inflammasome during infection-related Ali/Ards using prospectively collected Blood (n=100) and banked Plasma samples (n=600) from placebo- and statin-treated SAILS subjects. Gene expression and protein levels of Theinflammasome will be correlated with 60-day Mortality and additional SAILS trial secondary outcomes. We hypothesize that circulating inflammasome levels will serve as ABiomarker of severity and Mortality of infection-related Ali/Ards and that inflammasome levels in statin-treated subjects will correlate with Clinical outcomes. Specific Aim 2: To determine The cellular localization of expression of The inflammasome complex and Role of inflammasome activation on cellular responses and function, using primary neutrophils and monocytes isolated from prospectively enrolled placebo- and statin-treated SAILS subjects (n=100), as well as primary cells isolated from control ICU subjects (n=100). We hypothesize that determining which circulating cells are The predominant source of inflammasome activation will increase sensitivity of The correlation of inflammasome levels with Clinical outcomes and that localized activation of The inflammasome will result in mitochondrial dysfunction that will be enhanced in The presence of statin administration.